source
- Tango’s pancreatic cancer combo shows striking promise at ESMO, building on Revolution Medicines’ earlier successTango presented new data on its pancreatic cancer combination at the opening of the ESMO conference, highlighting a striking level of activity that builds on earlier success reported by Revolution…
- Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trialA recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…